Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Wei Zhou
Modality
mixture
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01819961CT.gov Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastric Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Triglycerides,Medium Chain (this asset) | Wei Zhou | Approved | BB · 65 |
| Fluorouracilum | Seagen, a wholly owned subsidiary of Pfizer | P4 | BBB |
| Capecitabine | SUNHO（China）BioPharmaceutical CO., Ltd. | P3 | BB |
| Oxaliplatin | SUNHO（China）BioPharmaceutical CO., Ltd. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Jazz Pharmaceuticals | P3 | BB |
| Pembrolizumab | Merck Sharp & Dohme LLC | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Trastuzumab | SUNHO（China）BioPharmaceutical CO., Ltd. | P3 | BB |
| S-1 | Merck Sharp & Dohme LLC | P3 | BB |
+42 more in the Gastric Neoplasm cohort
Other indications for Triglycerides,Medium Chain
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Neoplasm | — | P4 | BB · 65 |
| Liver And Intrahepatic Bile Duct Neoplasm | — | P4 | BB · 65 |
| Post-Traumatic Stress Disorder | — | P1 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Triglycerides,Medium Chain in Gastric Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/triglyceridesmedium-chain-gastric-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →